内质网应激与脂质代谢关系研究进展

肝脏 ›› 2022, Vol. 27 ›› Issue (4): 491-493.

内质网应激与脂质代谢关系研究进展

王晓凡, 谢超, 丛敏

100050 北京首都医科大学附属北京友谊医院肝病中心;肝硬化转化医学北京市重点实验室暨国家消化系统疾病临床医学研究中心

收稿日期:2021-08-06 出版日期:2022-04-30 发布日期:2022-06-02
通讯作者: 丛敏,Email:maomao0623@sina.com
基金资助:
国家自然科学基金(81570542);王宝恩肝纤维化基金(CFHPC 2021042)

Received:2021-08-06 Online:2022-04-30 Published:2022-06-02

摘要/Abstract

摘要： 内质网是调节钙稳态,脂质代谢,蛋白质合成以及翻译后修饰和运输的重要场所,是真核细胞维持机体正常的生理功能必不可少的细胞器。环境与病理等因素导致内质网稳态遭到破坏,大量未折叠或错误折叠蛋白质在管腔积累,引发内质网应激(ERS)。同时,未折叠蛋白级联反应(UPR)被激活,触发一系列转录和翻译事件,以恢复内质网稳态。然而,如果过度和(或)长时间的UPR仍无法逆转ERS,机体就会启动凋亡程序诱导细胞凋亡。越来越多的研究表明,ERS在脂质代谢过程中发挥着重要作用。

王晓凡, 谢超, 丛敏. 内质网应激与脂质代谢关系研究进展[J]. 肝脏, 2022, 27(4): 491-493.

参考文献

[1] Voeltz GK, Rolls MM, Rapoport TA. Structural organization of the endoplasmic reticulum. EMBO Rep, 2002, 3:944-950.
[2] González-Quiroz M, Blondel A, Sagredo A, et al. When endoplasmic reticulum proteostasis meets the DNA damage response. Trends Cell Bio, 2020, 30:881-891.
[3] Baiceanu A, Mesdom P, Lagouge M, et al. Endoplasmic reticulum proteostasis in hepatic steatosis. Nat Rev Endocrinol, 2016, 12:710-722.
[4] Hetz C, Martinon F, Rodriguez D, et al. The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiol Rev, 2011, 91:1219-1243.
[5] Xia SW, Wang ZM, Sun SM, et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease. Pharmacol Res, 2020, 161:105218.
[6] Lee KP, Dey M, Neculai D, et al. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell, 2008, 132:89-100.
[7] Maiers JL, Malhi H. Endoplasmic reticulum stress in metabolic liver diseases and hepatic fibrosis. Semin Liver Dis, 2019, 39:235-248.
[8] Moncan M, Mnich K, Blomme A, et al. Regulation of lipid metabolism by the unfolded protein response. J Cell Mol Med, 2021, 25:1359-1370.
[9] Karagöz GE, Aragón T, Acosta-Alvear D. Recent advances in signal integration mechanisms in the unfolded protein response. F1000Res, 2019, 8:F1000 Faculty Rev-1840.
[10] Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol, 2020, 21:421-438.
[11] Bommiasamy H, Back SH, Fagone P, et al. ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum. J Cell sci, 2009, 122:1626-1636.
[12] Sarvani C, Sireesh D, Ramkumar KM. Unraveling the role of ER stress inhibitors in the context of metabolic diseases. Pharmacol Res, 2017, 119:412-421.
[13] Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacol Ther, 2019, 203:107401.
[14] Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J hepatol, 2018, 69:927-947.
[15] Metcalf MG, Higuchi-Sanabria R, Garcia G, et al. Beyond the cell factory: homeostatic regulation of and by the UPR(ER). Sci Adv, 2020, 6:eabb9614.
[16] Zhang K, Wang S, Malhotra J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J, 2011, 30:1357-1375.
[17] Wang S, Chen Z, Lam V, et al. IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. Cell Metab, 2012, 16:473-486.
[18] Lee AH, Scapa EF, Cohen DE, et al. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science, 2008, 320:1492-1496.
[19] So JS, Hur KY, Tarrio M, et al. Silencing of lipid metabolism genes through IRE1α-mediated mRNA decay lowers plasma lipids in mice. Cell Metab, 2012, 16:487-499.
[20] Lebeaupin C, Vallée D, Rousseau D, et al. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. Hepatology, 2018, 68:515-532.
[21] Lauressergues E, Bert E, Duriez P, et al. Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? Neuropharmacology, 2012, 62:784-796.
[22] Oyadomari S, Harding HP, Zhang Y, et al. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab, 2008, 7:520-532.
[23] Xiao G, Zhang T, Yu S, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. J Biol Chem, 2013, 288:25350-25361.
[24] Jo H, Choe SS, Shin KC, et al. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. Hepatology, 2013, 57:1366-1377.
[25] Wang Y, Zhang L, Wu X, et al. The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice. Hepatology, 2013, 57:1005-1016.
[26] Chen X, Zhang F, Gong Q, et al. Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor α. Diabetes, 2016, 65:1904-1915.
[27] Usui M, Yamaguchi S, Tanji Y, et al. Atf6alpha-null mice are glucose intolerant due to pancreatic beta-cell failure on a high-fat diet but partially resistant to diet-induced insulin resistance. Metabolism, 2012, 61:1118-1128.
[28] Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 2004, 306:457-461.
[29] Rennert C, Heil T, Schicht G, et al. Prolonged lipid accumulation in cultured primary human hepatocytes rather leads to ER stress than oxidative stress. Int J Mol Sci, 2020, 21.
[30] Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol, 2016, 9:392-407.
[31] Jiang S, Yan C, Fang QC, et al. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem, 2014, 289:29751-29765.
[32] Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature, 2016, 529:326-335.
[33] Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52:472-479.
[34] Han KL, Choi JS, Lee JY, et al. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes, 2008, 57:737-745.